punicacortein B | 103488-36-4

• 分子结构分类: 有机化合物 - 苯丙烷和聚酮 - 单宁
• 英文名称: punicacortein B
• 英文别名: [(2R,3R)-3-[(14S,15S,19S)-2,3,4,7,8,9,19-heptahydroxy-12,17-dioxo-13,16-dioxatetracyclo[13.3.1.05,18.06,11]nonadeca-1,3,5(18),6,8,10-hexaen-14-yl]-2,3-dihydroxypropyl] 3,4,5-trihydroxybenzoate
• CAS: 103488-36-4
• 化学式: C₂₇H₂₂O₁₈
• 分子量: 634.461
• InChiKey: JYPJJOONMBTTAR-MEZSAOBOSA-N

物化性质

• 沸点：
  1321.4±65.0 °C(Predicted)
• 密度：
  1.976±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  -0.8
• 重原子数：
  45
• 可旋转键数：
  6
• 环数：
  6.0
• sp3杂化的碳原子比例：
  0.22
• 拓扑面积：
  322
• 氢给体数：
  12
• 氢受体数：
  18

反应信息

• 作为反应物：
  描述：

  punicacortein B 在 单宁酶 作用下， 以 水 为溶剂， 反应 3.0h， 生成 没食子酸 、 degalloyl-punicacortein A
  参考文献：
  名称：

  Tannins and related compounds. XLI. Isolation and characterization of novel ellagitannins, punicacorteins A, B, C and D, and punigluconin from the bark of Punica granatum L.

  摘要：

  对石榴（Punica granatum L.）树皮的化学分析导致分离出五种新的椰子单宁，分别是punicacorteins A、B、C和D，以及punigluconin，同时还发现了已知的椰子单宁，casuariin（6）和casuarinin（7）。基于化学和光谱证据，确定了punicacorteins A、B、C和D的结构为新型C-糖苷类型的椰子单宁，其中前两种具有独特的四苯基（gallagyl）酯基团（1和2），而后两种则在其位置替换为没食子酰基（3和4）。同时，punigluconin被表征为2, 3-二-O-没食子酰-4, 6-(S)-六羟基二苯酰葡萄糖酸（5）。

  DOI：

  10.1248/cpb.34.656

文献信息

• Compositions and Methods for Improving Mitochondrial Function and Treating Neurodegenerative Diseases and Cognitive Disorders
  申请人：Amazentis SA

  公开号：US20170143667A1

  公开（公告）日：2017-05-25

  Provided are compositions comprising compounds or precursors to compounds which may be used for a variety of therapeutic applications including, for example, treating and/or preventing a disease or disorder related to reduced or inadequate mitochondrial activity, including aging or stress, diabetes, obesity, and neurodegenerative diseases. The compounds relate generally to urolithins and precursors thereof, including but not limited to ellagitannins and urolithin A. In certain embodiments the compositions are presented in or as food products or nutritional supplements. These same compounds and compositions can also be used advantageously in generally healthy individuals to increase or maintain metabolic rate, decrease percent body fat, increase or maintain muscle mass, manage body weight, improve or maintain mental performance (including memory), improve or maintain muscle performance, improve or maintain mood, and manage stress.

  提供了一些化合物或化合物前体的组合物，可用于各种治疗应用，包括治疗和/或预防与线粒体活性降低或不足有关的疾病或障碍，包括衰老或压力、糖尿病、肥胖症和神经退行性疾病等。这些化合物通常与石榴酸单宁和尿石榴素A等尿石榴素有关。在某些实施例中，这些组合物以食品产品或营养补充剂的形式呈现。这些相同的化合物和组合物也可以在通常健康的个体中有益地用于增加或维持代谢率，减少体脂百分比，增加或维持肌肉质量，管理体重，改善或维持心理表现（包括记忆），改善或维持肌肉表现，改善或维持情绪，以及管理压力。
• COMPOSITIONS AND METHODS FOR IMPROVING MITOCHONDRIAL FUNCTION AND TREATING NEURODEGENERATIVE DISEASES AND COGNITIVE DISORDERS
  申请人：Amazentis SA

  公开号：US20170143666A1

  公开（公告）日：2017-05-25

  Provided are compositions comprising compounds or precursors to compounds which may be used for a. variety of therapeutic applications including, for example, treating and/or preventing a disease or disorder related to reduced or inadequate mitochondrial activity, including aging or stress, diabetes, obesity, and neurodegenerative diseases. The compounds relate generally to urolithins and precursors thereof, including but not limited to ellagitannins and uroiithin A. In certain embodiment the compositions are presented in or as food products or nutritional supplements. These same compounds and compositions can also be used advantageously in generally healthy individuals to increase or maintain metabolic rate, decrease percent body fat, increase or maintain muscle mass, manage body weight, improve or maintain mental performance (including memory), improve or maintain muscle performance, improve or maintain mood, and manage stress.

  提供的是包含化合物或其前体的组合物，可用于各种治疗应用，包括但不限于治疗与线粒体活性降低或不足有关的疾病或紊乱，如衰老或压力、糖尿病、肥胖症和神经退行性疾病。这些化合物通常与石榴酸单宁和尿石榴素A有关。在某些实施例中，这些组合物以食品产品或营养补充剂的形式呈现。这些相同的化合物和组合物也可用于一般健康的人，以增加或维持代谢率，降低身体脂肪百分比，增加或维持肌肉质量，管理体重，改善或维持心理表现（包括记忆），改善或维持肌肉表现，改善或维持情绪，以及管理压力。
• Enhancing Autophagy or Increasing Longevity by Administration of Urolithins or Precursors Thereof
  申请人：Amazentis SA

  公开号：US20140018415A1

  公开（公告）日：2014-01-16

  Disclosed are methods, compounds, and compositions useful for increasing autophagy and promoting longevity. The methods, compounds, and compositions relate to urolithins and urolithin precursors and use thereof. Certain urolithins are represented by Formula I, while certain urolithin precursors are represented by Formula IV. The urolithin may be urolithin A, urolithin B, urolithin C, or urolithin D. The urolithin precursor may be ellagic acid or an ellagitannin. The methods include in vivo, ex vivo, and in vitro uses of the compounds and compositions.

  本发明涉及用于增加自噬和促进寿命的方法、化合物和组合物。所述方法、化合物和组合物涉及urolithins和urolithin前体及其使用。某些urolithins由公式I表示，而某些urolithin前体由公式IV表示。所述urolithin可以是urolithin A、urolithin B、urolithin C或urolithin D。所述urolithin前体可以是鞣花酸或鞣花酸单宁。所述方法包括化合物和组合物的体内、体外和体外使用。
• Compositions and methods for improving mitochondrial function and treating neurodegenerative diseases and cognitive disorders
  申请人：Amazentis SA

  公开号：US10028932B2

  公开（公告）日：2018-07-24

  Provided are compositions comprising compounds or precursors to compounds which may be used for a variety of therapeutic applications including, for example, treating and/or preventing a disease or disorder related to reduced or inadequate mitochondrial activity, including aging or stress, diabetes, obesity, and neurodegenerative diseases. The compounds relate generally to urolithins and precursors thereof, including but not limited to ellagitannins and urolithin A. In certain embodiments the compositions are presented in or as food products or nutritional supplements. These same compounds and compositions can also be used advantageously in generally healthy individuals to increase or maintain metabolic rate, decrease percent body fat, increase or maintain muscle mass, manage body weight, improve or maintain mental performance (including memory), improve or maintain muscle performance, improve or maintain mood, and manage stress.

  本发明提供了包含化合物或化合物前体的组合物，可用于多种治疗应用，包括治疗和/或预防与线粒体活性降低或不足有关的疾病或紊乱，包括衰老或应激、糖尿病、肥胖和神经退行性疾病。这些化合物一般与尿石素及其前体有关，包括但不限于鞣花丹宁酸和尿石素 A。这些相同的化合物和组合物也可用于一般健康人，以提高或维持新陈代谢率、降低体脂百分比、增加或维持肌肉质量、控制体重、改善或维持智力表现（包括记忆力）、改善或维持肌肉表现、改善或维持情绪以及控制压力。
• Enhancing autophagy or increasing longevity by administration of urolithins or precursors thereof
  申请人：Amazentis SA

  公开号：US11020373B2

  公开（公告）日：2021-06-01

  Disclosed are methods, compounds, and compositions useful for increasing autophagy and promoting longevity. The methods, compounds, and compositions relate to urolithins and urolithin precursors and use thereof. Certain urolithins are represented by Formula I, while certain urolithin precursors are represented by Formula IV. The urolithin may be urolithin A, urolithin B, urolithin C, or urolithin D. The urolithin precursor may be ellagic acid or an ellagitannin. The methods include in vivo, ex vivo, and in vitro uses of the compounds and compositions.

  本发明公开了有助于增加自噬和促进长寿的方法、化合物和组合物。这些方法、化合物和组合物与尿石素和尿石素前体及其用途有关。某些尿磷脂由式 I 表示，而某些尿磷脂前体由式 IV 表示。尿石素可以是尿石素 A、尿石素 B、尿石素 C 或尿石素 D。尿石素前体可以是鞣花酸或鞣花丹宁。这些方法包括化合物和组合物的体内、体外和体外使用。